Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation

Liver Transplantation

Volumn 13, Issue 6, 2007, Pages 913-917

  Saraf, Neeraj ^a   Fiel, M Isabel ^b   DeBoccardo, Graciela ^c   Emre, Sukru ^c   Schiano, Thomas D ^a,c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Lillian Henry M Stratton Hans P   (United States)

^c Recanati/Miller Transplantation Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; DACLIZUMAB; PREDNISONE; TACROLIMUS; VIRUS RNA;

AGED; ARTICLE; CADAVER DONOR; CASE REPORT; DEATH; DETERIORATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RECURRENT INFECTION; SURVIVAL TIME; VIRUS LOAD;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TIME FACTORS;

EID: 34250625261     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21188     Document Type: Article

References (33)

1. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-678.
2. Wiesner RH, Sorrell M, Villamil F; International Liver Transplantation Society Expert Panel. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-S9.
3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28-S34.
4. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004;40:368-374.
5. Brovn RS. Hepatitis C and liver transplantation. Nature 2005;436:973-978.
6. Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayon M, San Juan F, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003;9:1152-1158.
7. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226-231.
8. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
9. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10 year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001:23:384-394.
10. Greenson JK, Svoboda-Newman SM, Merion RM, Frank TS. Histological progression of recurrent hepatitis C in liver transplant allografts. Am J Surg Path 1996;2:731-738.
11. Shiffman ML, Stravitz RT, Contos MJ, Mills AS, Sterling RK, Luketic VA, et al. Histological recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004;10: 1248-1255.
12. Schiano TD, Gutierrez JA, Walewski JL, Fiel MI, Cheng B, Bodenheimer H, et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005;42: 1420-1428.
13. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707.
14. Guerrero RB, Batts KP, Burgart LJ, Barrett SL, Germer JJ, Poterucha JJ, et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000;13: 229-237.
15. Regev A, Molina E, Moura R, Bejarano PA, Khaled A, Ruiz P, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004;10: 1233-1239.
16. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19:1409-1417.
17. Takeishi T, Sato Y, Ichida S, Yamamoto S, Hirano K, Kobayashi T, et al. Rapid progressive hepatitis C after liver transplantation: a case report. Transplant Proceed 2004; 36:2304.
18. Berenguer M. Host and donor pre- and post-liver transplant risk factors impacting on HCV recurrence. Liver Transpl 2003;9:S44-S47.
19. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
20. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
21. Machicao VI, Bonatti H, Krishna M, Agel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
22. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003;9:S63-S66.
23. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European Collaborative Study on factors influencing the outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-625.
24. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
25. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation with particular reference to hepatitis C virus. Transplantation 2004;78: 966-971.
26. Nelson DR, Soldevila-Pico, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;12:1064-1070.
27. Levy MF, Somasundar PS, Jennings LW, Jung GJ, Molmenti EP, Fasola CG, et al. The elderly liver transplant recipient: a call for caution. Ann Surg 2001;233:107-113.
28. Carmiel-Haggai M, Fiel MI, Gaddipati HC, Abittan C, Hossain S, Roayaie S, et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 2005;11:1567-1573.
29. Toniutto P, Fabris C, Bortolotti N, Minisini R, Avellini C, Fumo E, et al. Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantation. J Hepatol 2004;41:307-311.
30. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003; 9:48-51.
31. Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using hepatitis (+) allografts. Liver Transpl 2006;12:1496-1503.
32. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000;6:44-53.
33. Scheuer P, Lefkowitch J. Liver Biopsy Interpretation. London: WB Saunders; 2000:41-42.